Research Study
Nifty Biosimilar
![Nifty Biosimilar](/var/wrbm_gb_food_pharma/storage/images/_aliases/wrbm_product_file/publications/pharmaceutical-science/biopharma-reporter.com/library/nifty-biosimilar/7911970-1-eng-GB/Nifty-Biosimilar.png)
Aflibercept (Zaltrap®) is a recombinant fusion protein with complex post-translational modifications. Therefore deep understanding of biosimilar development is required to develop a biosimilar like Aflibercept.
UGA Biopharma has successfully completed a large number of biosimilar for several international biopharmaceutical companies. Our know-how and longstanding expertise in cell line development, bioprocess optimization, downstream development and analytics makes us the leading partner for your biosimilar development projects